Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Could Some Cancer Drugs Protect Against COVID-19?

Could Some Cancer Drugs Protect Against COVID-19?

A new study suggests that certain cancer drugs that lower levels of a receptor called angiotensin-converting enzyme 2 (ACE2), which is found on the surface of human cells and allows the coronavirus to attach, may provide some protection against COVID-19 infection.

These cancer drugs include TOR/PI3K inhibitors (everolimus, temsirolimus and alpelisib), antimetabolites (decitabine and gemcitabine), mitotic inhibitors (cabazitaxel) and other kinase inhibitors (dasatinib and crizotinib).

The study, conducted at Memorial Sloane Kettering Center (MSKCC) in New York City between March 10 and May 28, 2020, during the early months of the COVID-19 pandemic, included 1701 patients receiving cancer treatment.

The researchers found that patients treated with cancer drugs that lower ACE2 levels had a significantly lower rate of SARS-CoV-2 test positivity than patients receiving other drugs (7% versus 12.9%).

Study author Michael Foote, a research fellow at MSKCC, said of the study: “Many oncologists worry that treating patients with certain cancer drugs may increase their risk of COVID-19. Because of this paper, some oncologists may feel a little more comfortable treating a patient with a particular drug on our list during the pandemic.”

He also suggested that the findings could stimulate new research. There is considerable interest in discovering new molecular signaling patterns that the virus uses to survive and multiply. A reduction in viruses' ability to enter cells with certain compounds suggests that they may disrupt the specific signaling pathways SARS-CoV-2 needs to replicate. Further research could explore these new viral signaling pathways in a laboratory to better understand how the virus multiplies and potentially design new antiviral drugs for all patients, not just those with cancer.

The study was published online on August 19 in JAMA Oncology.

In the first part of their study, the team used computer simulation to identify cancer drugs associated with reduced ACE2 gene expression. They then evaluated patients receiving these drugs during the pandemic.

Of the 1701 study participants, 215 (12.6%) received an ACE2-lowering cancer drug.

Gemcitabine chemotherapy in particular was associated with reduced SARS-CoV-2 positivity (odds ratio 0.42).

It should be remembered that this study was a retrospective analysis, rather than a randomized controlled clinical trial. Randomized controlled clinical trials are the gold standard for determining whether a drug works for a patient.

These findings also come from very early in the pandemic, before COVID-19 vaccines were available. This study may be meaningful because it evaluated some drugs' effects on the virus before vaccination.

However, with effective vaccines now available, it is unclear how these findings should be applied. We certainly know that vaccines are the most effective way to prevent viral spread. The delta variant has been shown to have a particularly strong interaction between the virus and the ACE2 receptor; whether the cancer drugs would be more or less effective against this variant is unknown.

*

RELATED TOPICS

Sources

Foote MB, White JR, Jee J, et al. Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer. JAMA Oncol. Published online August 19, 2021. doi:10.1001/jamaoncol.2021.3585

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Could Some Cancer Drugs Protect Against COVID-19?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy